萨库比特里尔/瓦尔萨坦与对HFrEF患者运动能力的标准医疗治疗
Alfonso Campanile1, Valeria Visco2, Stefania De Carlo3
1Cardiology Unit, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84131 Salerno, Italy.
Life (Basel, Switzerland)
|May 27, 2023
概括
与标准治疗相比,萨库比特里尔/瓦尔沙坦 (Sac/Val) 在心力衰竭中没有改善心力衰竭患者的功能能力. 16个月后,心肺运动测试 (CPET) 在峰值VO2或VE/VCO2斜率上没有显著差异.
科学领域:
- 心脏病学 心脏病学
- 运动生理学 运动生理学
背景情况:
- 已知萨库比特里尔/瓦尔沙坦 (Sac/Val) 可以降低心力衰竭的死亡率,并减少排气分数 (HFrEF).
- 通过心肺运动测试 (CPET) 评估的Sac/Val对功能能力的影响,在HFrEF患者中仍然不太了解.
研究的目的:
- 为了比较Sac/Val与标准医学治疗对HFrEF患者预后显著CPET参数的影响.
- 为了评估峰值氧气消耗 (VO2) 和通风/二氧化碳生产斜率 (VE/VCO2) 在16个月的中位随访期间的变化.
主要方法:
- 一个单一中心的观察性研究回顾分析了12名HFrEF患者转换为Sac/Val和13名标准治疗 (对照组).
- 收集的数据包括人口统计,病史,生命体征,CPET,实验室结果,以及基线和随访时的心声图.
- 主要终点是根据体重调整的VO2峰值的变化.
主要成果:
- 在基线时,Sac/Val和对照组之间没有发现显著差异.
- 经过16个月的中位随访后,两组之间的平均峰值VO2 (mL/kg/min) 没有发现显著差异 (Sac/Val:12.7 ± 3.3与对照组:13.0 ± 4.2;p=0.49).
- 同样,在两组之间的VE/VCO2斜率上也没有发现显著差异 (Sac/Val: 37.2 ± 13.1与对照: 34.0 ± 7.3;p=0.49).
结论:
- 与HFrEF患者的标准最佳治疗相比,sacubitril/valsartan在峰值VO2或其他CPET测量上没有显著的益处.
- 这些发现表明,在16个月的随访期间,Sac/Val可能不会在这个患者群体中显著改善CPET评估的功能能力.
更多相关视频
02:47Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
1.4K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.5K
相关概念视频
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
471
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
471
01:22Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
01:25Aortic Regurgitation III: Medical Management
27
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
27
01:22Heart Failure Drugs: Diuretics
430
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
430
01:29Cardiomyopathy V: Interprofessional Care
19
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
19